Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Engaging T cells for cleanup

RV. Mungalov, NV. Mushenkova, DM. Chudakov, MA. Turchaninova

. 2025 ; 16 (-) : 1551424. [pub] 20250506

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015787

T-cell engagers represent a transformative approach to cancer immunotherapy leveraging bispecific and multispecific antibody constructs to redirect T-cell cytotoxicity toward malignant cells. These molecules bridge T cells and tumor cells by simultaneously binding CD3 on T cells and tumor-associated antigens on cancer cells, thereby enabling precise immune targeting even in immunologically "cold" tumors. Recent advancements include conditional T-cell engagers activated by tumor microenvironment proteases to minimize off-tumor toxicity as well as T-cell receptor-based engagers targeting intracellular antigens via MHC presentation. Clinical successes, such as Kimmtrak in metastatic uveal melanoma, underscore good potential of these modalities, while challenges persist in the management of cytokine release syndrome, neurotoxicity, and tumor resistance. Emerging multispecific engagers are aimed at enhancing efficacy via incorporation of costimulatory signals, thus offering a promising trajectory for next-generation immunotherapies. T-cell engagers are also gaining attention in the treatment of autoimmune disorders, where they can be designed to selectively modulate pathogenic immune responses. By targeting autoreactive T or B cells, T-cell engagers hold promise for restoring immune tolerance in such conditions as HLA-B*27-associated autoimmunity subtypes, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes mellitus. Engineering strategies that incorporate inhibitory receptors or tissue-specific antigens may further refine T-cell engagers' therapeutic potential in autoimmunity, by minimizing systemic immunosuppression while preserving immune homeostasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015787
003      
CZ-PrNML
005      
20250731091232.0
007      
ta
008      
250708e20250506sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2025.1551424 $2 doi
035    __
$a (PubMed)40416957
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mungalov, Roman V $u Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia $u Genomics of Adaptive Immunity Department, Institute of Bioorganic Chemistry, Moscow, Russia $u Faculty of Biology and Biotechnology, Higher School of Economics, Moscow, Russia
245    10
$a Engaging T cells for cleanup / $c RV. Mungalov, NV. Mushenkova, DM. Chudakov, MA. Turchaninova
520    9_
$a T-cell engagers represent a transformative approach to cancer immunotherapy leveraging bispecific and multispecific antibody constructs to redirect T-cell cytotoxicity toward malignant cells. These molecules bridge T cells and tumor cells by simultaneously binding CD3 on T cells and tumor-associated antigens on cancer cells, thereby enabling precise immune targeting even in immunologically "cold" tumors. Recent advancements include conditional T-cell engagers activated by tumor microenvironment proteases to minimize off-tumor toxicity as well as T-cell receptor-based engagers targeting intracellular antigens via MHC presentation. Clinical successes, such as Kimmtrak in metastatic uveal melanoma, underscore good potential of these modalities, while challenges persist in the management of cytokine release syndrome, neurotoxicity, and tumor resistance. Emerging multispecific engagers are aimed at enhancing efficacy via incorporation of costimulatory signals, thus offering a promising trajectory for next-generation immunotherapies. T-cell engagers are also gaining attention in the treatment of autoimmune disorders, where they can be designed to selectively modulate pathogenic immune responses. By targeting autoreactive T or B cells, T-cell engagers hold promise for restoring immune tolerance in such conditions as HLA-B*27-associated autoimmunity subtypes, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes mellitus. Engineering strategies that incorporate inhibitory receptors or tissue-specific antigens may further refine T-cell engagers' therapeutic potential in autoimmunity, by minimizing systemic immunosuppression while preserving immune homeostasis.
650    _2
$a lidé $7 D006801
650    12
$a T-lymfocyty $x imunologie $x metabolismus $7 D013601
650    _2
$a zvířata $7 D000818
650    12
$a imunoterapie $x metody $7 D007167
650    12
$a nádory $x imunologie $x terapie $7 D009369
650    _2
$a protilátky bispecifické $x terapeutické užití $x imunologie $7 D018033
650    _2
$a receptory antigenů T-buněk $x imunologie $x metabolismus $7 D011948
650    _2
$a nádorové mikroprostředí $x imunologie $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Mushenkova, Natalia V $u Genomics of Adaptive Immunity Department, Institute of Bioorganic Chemistry, Moscow, Russia $u Unicorn Capital Partners, Moscow, Russia
700    1_
$a Chudakov, Dmitriy M $u Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia $u Genomics of Adaptive Immunity Department, Institute of Bioorganic Chemistry, Moscow, Russia $u Center for Molecular and Cellular Biology, Moscow, Russia $u Department of Molecular Medicine, Central European Institute of Technology, Brno, Czechia $u Abu Dhabi Stem Cell Center, Al Muntazah, United Arab Emirates
700    1_
$a Turchaninova, Maria A $u Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia $u Genomics of Adaptive Immunity Department, Institute of Bioorganic Chemistry, Moscow, Russia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 16 (20250506), s. 1551424
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40416957 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091226 $b ABA008
999    __
$a ok $b bmc $g 2366555 $s 1252912
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 16 $c - $d 1551424 $e 20250506 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace